haloperidol has been researched along with cabergoline in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N | 1 |
| Battaglia, A; Canonico, PL; Lombardi, G; Miglio, G; Papini, MG; Varsaldi, F | 1 |
| Battaglia, A; Canonico, PL; Francioli, E; Lombardi, G; Miglio, G; Varsaldi, F | 1 |
| Frank, MJ; O'Reilly, RC | 1 |
| Arany, E; Becu-Villalobos, D; Chamson-Reig, A; García-Tornadú, I; Hill, DJ; Ornstein, AM; Rubinstein, M; Wheeler, MB | 1 |
| Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E | 1 |
| Anheim, M; Benabid, AL; Chabardès, S; Dowsey-Limousin, P; Krack, P; Pollak, P | 1 |
1 review(s) available for haloperidol and cabergoline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for haloperidol and cabergoline
| Article | Year |
|---|---|
A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol.
Topics: Adolescent; Adult; Attention; Cabergoline; Choice Behavior; Cognition; Computer Simulation; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Ergolines; Female; Generalization, Psychological; Haloperidol; Humans; Male; Memory, Short-Term; Models, Neurological; Neuropsychological Tests; Probability Learning; Prolactin; Young Adult | 2006 |
8 other study(ies) available for haloperidol and cabergoline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Striatum; Denervation; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Ergolines; Female; Gene Expression Regulation; Genes, fos; Haloperidol; Indoles; Macaca fascicularis; Male; Molecular Weight; MPTP Poisoning; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Phenanthridines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, Dopamine D1; RNA, Messenger; Species Specificity; Time Factors; Transcription Factors | 1996 |
Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress.
Topics: Cabergoline; Cell Death; Cell Survival; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Ergolines; Free Radicals; Haloperidol; Humans; Lipid Peroxidation; Models, Neurological; Necrosis; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Receptors, Dopamine D2; tert-Butylhydroperoxide; Tumor Cells, Cultured | 2002 |
Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia.
Topics: Animals; Antioxidants; Cabergoline; Cell Death; Cell Hypoxia; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ergolines; Free Radical Scavengers; Free Radicals; Gene Expression; Genes, bcl-2; Glucose; Haloperidol; Humans; Ischemia; Neurons; Thiobarbituric Acid Reactive Substances; Time Factors; Tretinoin; Vitamin E | 2004 |
Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance.
Topics: Analysis of Variance; Animals; Blood Glucose; Cabergoline; Cell Proliferation; Dopamine Agonists; Dopamine Antagonists; Ergolines; Female; Glucose; Glucose Intolerance; Haloperidol; Immunohistochemistry; Insulin; Insulin Secretion; Insulin-Like Growth Factor I; Male; Mice; Mice, Knockout; Pancreas; Prolactin; Radioimmunoassay; Receptors, Dopamine D2; Time Factors | 2010 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Haloperidol; Humans; Hyperprolactinemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Prolactin; Prospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sexual Dysfunction, Physiological; Sulpiride | 2013 |
Subthalamic stimulation or subthalamic lesion for Parkinson's disease? A case report.
Topics: Adult; Antiparkinson Agents; Cabergoline; Chorea; Combined Modality Therapy; Deep Brain Stimulation; Equipment Failure; Ergolines; Female; Haloperidol; Humans; Magnetic Resonance Imaging; Parkinson Disease; Recurrence; Severity of Illness Index; Subthalamic Nucleus | 2015 |